Announcement • Apr 02
DuoGenic StemCells corporation, Annual General Meeting, Jun 25, 2026 DuoGenic StemCells corporation, Annual General Meeting, Jun 25, 2026, at 10:00 Taipei Standard Time. Location: b1 floor no,145, hsing ta rd., south district, taichung city Taiwan Board Change • Feb 25
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Aug 01
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: NT$296.4m (US$9.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$10m (NT$296.4m market cap, or US$9.90m).